• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用透气表面从 CD34 细胞体外大规模生成巨核细胞。

Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34 Cells Using Gas-Permeable Surfaces.

机构信息

Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois, USA.

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.

出版信息

Stem Cells Transl Med. 2019 Jul;8(7):658-670. doi: 10.1002/sctm.18-0160. Epub 2019 Mar 8.

DOI:10.1002/sctm.18-0160
PMID:30848565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6591548/
Abstract

Patients suffering from acute or sustained thrombocytopenia require platelet transfusions, which are entirely donor-based and limited by challenges related to storage and fluctuating supply. Developing cell-culture technologies will enable ex vivo and donor-independent platelet production. However, critical advancements are needed to improve scalability and increase megakaryocyte (Mk) culture productivity. To address these needs, we evaluated Mk production from mobilized peripheral blood CD34 cells cultured on a commercially available gas-permeable silicone rubber membrane, which provides efficient gas exchange, and investigated the use of fed-batch media dilution schemes. Starting with a cell-surface density of 40 × 10 CD34 cells per cm (G40D), culturing cells on the membrane for the first 5 days and employing media dilutions yielded 39 ± 19 CD41 CD42b Mks per input CD34 cell by day 11-a 2.2-fold increase compared with using standard culture surfaces and full media exchanges. By day 7, G40D conditions generated 1.5-fold more CD34 cells and nearly doubled the numbers of Mk progenitors. The increased number of Mk progenitors coupled with media dilutions, potentially due to the retention of interleukin (IL)-3, increased Mk production in G40D. Compared with controls, G40D had higher viability, yielded threefold more Mks per milliliter of media used and exhibited lower mean ploidy, but had higher numbers of high-ploidy Mks. Finally, G40D-Mks produced proplatelets and platelet-like-particles that activate and aggregate upon stimulation. These results highlight distinct improvements in Mk cell-culture and demonstrate how new technologies and techniques are needed to enable clinically relevant production of Mks for platelet generation and cell-based therapies.

摘要

患有急性或持续性血小板减少症的患者需要进行血小板输注,而这些输注完全依赖供体,并且受到与储存和波动供应相关的挑战的限制。开发细胞培养技术将能够实现离体和供体独立的血小板生产。然而,需要取得重大进展来提高可扩展性并增加巨核细胞(Mk)培养的生产力。为了解决这些需求,我们评估了在商业上可获得的透气硅橡胶膜上培养的动员外周血 CD34 细胞的 Mk 生产,该膜可实现有效的气体交换,并研究了使用分批补料培养基稀释方案。从细胞表面密度为 40×10 CD34 细胞/cm(G40D)开始,在膜上培养细胞 5 天,然后进行培养基稀释,到第 11 天,每个输入 CD34 细胞可获得 39±19 CD41 CD42b Mk,与使用标准培养表面和完全培养基交换相比增加了 2.2 倍。到第 7 天,G40D 条件生成的 CD34 细胞增加了 1.5 倍,Mk 祖细胞的数量几乎增加了一倍。增加的 Mk 祖细胞数量加上培养基稀释,可能是由于白细胞介素(IL)-3 的保留,增加了 G40D 中的 Mk 生成。与对照相比,G40D 的活力更高,每毫升使用的培养基产生的 Mk 增加了三倍,并且平均倍性降低,但高倍性 Mk 的数量增加。最后,G40D-Mks 产生了原血小板和血小板样颗粒,这些颗粒在刺激下激活和聚集。这些结果突出了 Mk 细胞培养的明显改进,并展示了如何需要新技术和技术来实现临床上相关的 Mk 生产,以用于血小板生成和基于细胞的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/5939af7692cd/SCT3-8-658-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/fc17ed2e3742/SCT3-8-658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/ae6e02296f2b/SCT3-8-658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/c04d537945e7/SCT3-8-658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/eddcff40430d/SCT3-8-658-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/60e74b0a5370/SCT3-8-658-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/e81dd6e8ea72/SCT3-8-658-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/5939af7692cd/SCT3-8-658-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/fc17ed2e3742/SCT3-8-658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/ae6e02296f2b/SCT3-8-658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/c04d537945e7/SCT3-8-658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/eddcff40430d/SCT3-8-658-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/60e74b0a5370/SCT3-8-658-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/e81dd6e8ea72/SCT3-8-658-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0be/6591548/5939af7692cd/SCT3-8-658-g007.jpg

相似文献

1
Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34 Cells Using Gas-Permeable Surfaces.利用透气表面从 CD34 细胞体外大规模生成巨核细胞。
Stem Cells Transl Med. 2019 Jul;8(7):658-670. doi: 10.1002/sctm.18-0160. Epub 2019 Mar 8.
2
Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: toward large-scale platelet production.三阶段体外扩增高倍体巨核细胞:实现大规模血小板生产。
Tissue Eng Part A. 2013 Apr;19(7-8):998-1014. doi: 10.1089/ten.TEA.2011.0111. Epub 2013 Jan 14.
3
Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.受骨髓龛启发的巨核细胞祖细胞的多相扩增,具有高多倍体化潜力。
Cytotherapy. 2010 Oct;12(6):767-82. doi: 10.3109/14653241003786148.
4
Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.巨核细胞祖细胞的体外扩增:多种生长因子组合对来自骨髓和粒细胞集落刺激因子动员的外周血的CD34+祖细胞的影响。
Exp Hematol. 1997 Oct;25(11):1125-39.
5
Effects of cytokines on platelet production from blood and marrow CD34+ cells.细胞因子对血液和骨髓CD34+细胞血小板生成的影响。
Blood. 1998 Feb 1;91(3):830-43.
6
Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells.从富集的外周血CD34+细胞中对CD34+/CD41+晚期祖细胞进行体外扩增。
Ann Hematol. 2000 Jan;79(1):13-9. doi: 10.1007/s002770050003.
7
Covalently immobilized glycosaminoglycans enhance megakaryocyte progenitor expansion and platelet release.共价固定糖胺聚糖可增强巨核细胞祖细胞的扩增和血小板释放。
J Biomed Mater Res A. 2011 Mar 15;96(4):682-92. doi: 10.1002/jbm.a.33024. Epub 2011 Jan 25.
8
Ex vivo expansion of megakaryocyte progenitor cells: cord blood versus mobilized peripheral blood.巨核细胞祖细胞的体外扩增:脐血与动员外周血的比较
Stem Cells Dev. 2005 Aug;14(4):415-24. doi: 10.1089/scd.2005.14.415.
9
Ex vivo expansion of early and late megakaryocyte progenitors.早期和晚期巨核细胞祖细胞的体外扩增。
J Hematother Stem Cell Res. 2000 Dec;9(6):913-21. doi: 10.1089/152581600750062363.
10
Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand.在血小板生成素以及有限量的干细胞因子和Flt-3配体存在的情况下,人脐带血富集CD34+细胞的巨核细胞在体外优先扩增。
J Hematother Stem Cell Res. 2003 Apr;12(2):179-88. doi: 10.1089/152581603321628322.

引用本文的文献

1
Inside-to-outside and back to the future of megakaryopoiesis.巨核细胞生成的由内而外与回归未来
Res Pract Thromb Haemost. 2023 May 30;7(4):100197. doi: 10.1016/j.rpth.2023.100197. eCollection 2023 May.
2
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.工程化脐血细胞巨核细胞逃避同种异体 T 细胞对难治性血小板减少症的杀伤作用。
Front Immunol. 2022 Sep 20;13:1018047. doi: 10.3389/fimmu.2022.1018047. eCollection 2022.
3
Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer.

本文引用的文献

1
Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.湍流激活血小板生成以实现临床规模的体外生产。
Cell. 2018 Jul 26;174(3):636-648.e18. doi: 10.1016/j.cell.2018.06.011. Epub 2018 Jul 12.
2
Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors.微载体支持的搅拌悬浮生物反应器中巨核细胞的大规模生产。
Sci Rep. 2018 Jul 5;8(1):10146. doi: 10.1038/s41598-018-28459-x.
3
Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.
超越血栓:血小板启发的纳米医学方法在炎症、免疫反应和癌症中的应用。
J Thromb Haemost. 2022 Jul;20(7):1523-1534. doi: 10.1111/jth.15733. Epub 2022 May 22.
4
Differentiated Cells Derived from Hematopoietic Stem Cells and Their Applications in Translational Medicine.造血干细胞来源的分化细胞及其在转化医学中的应用。
Adv Exp Med Biol. 2021;1347:29-43. doi: 10.1007/5584_2021_644.
5
The Blood Circulating Rare Cell Population. What is it and What is it Good For?循环血液稀有细胞群体。它是什么,有什么用?
Cells. 2020 Mar 25;9(4):790. doi: 10.3390/cells9040790.
利用小分子抑制剂增强体外培养巨核细胞体内功能性血小板释放。
Blood Adv. 2018 Mar 27;2(6):597-606. doi: 10.1182/bloodadvances.2017010975.
4
Fast recovery of platelet production in NOD/SCID mice after transplantation with expansion of megakaryocyte from cord blood CD34+ cells.用来自脐带血CD34+细胞的巨核细胞扩增物移植后,NOD/SCID小鼠的血小板生成快速恢复。
J Cancer Res Ther. 2018 Jan;14(1):233-239. doi: 10.4103/0973-1482.193893.
5
Megakaryocyte and polyploidization.巨核细胞与多倍体化
Exp Hematol. 2018 Jan;57:1-13. doi: 10.1016/j.exphem.2017.10.001. Epub 2017 Oct 27.
6
Current status of blood 'pharming': megakaryoctye transfusions as a source of platelets.血液“制药”的现状:以巨核细胞输血作为血小板来源
Curr Opin Hematol. 2017 Nov;24(6):565-571. doi: 10.1097/MOH.0000000000000378.
7
Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications.用于疾病建模和未来临床应用的诱导多能干细胞衍生的巨核细胞和血小板
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2007-2013. doi: 10.1161/ATVBAHA.117.309197. Epub 2017 Oct 5.
8
A uniform-shear rate microfluidic bioreactor for real-time study of proplatelet formation and rapidly-released platelets.一种用于实时研究前血小板形成和快速释放血小板的均匀剪切速率微流控生物反应器。
Biotechnol Prog. 2017 Nov;33(6):1614-1629. doi: 10.1002/btpr.2563. Epub 2017 Oct 13.
9
Platelet production from induced pluripotent stem cells.诱导多能干细胞生成血小板。
J Thromb Haemost. 2017 Sep;15(9):1717-1727. doi: 10.1111/jth.13736. Epub 2017 Jul 28.
10
Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.迈向用于临床应用的巨核细胞和血小板的制造。
Transfus Med Hemother. 2017 Jun;44(3):165-173. doi: 10.1159/000477261. Epub 2017 May 23.